From owner-doc-jp@jp.FreeBSD.org Wed Feb  6 22:06:05 2002
Received: (from daemon@localhost)
	by castle.jp.FreeBSD.org (8.11.6+3.4W/8.11.3) id g16D65D58761;
	Wed, 6 Feb 2002 22:06:05 +0900 (JST)
	(envelope-from owner-doc-jp@jp.FreeBSD.org)
Received: from epicac (eniac.cable.net.co [196.27.25.66])
	by castle.jp.FreeBSD.org (8.11.6+3.4W/8.11.3) with ESMTP/inet id g16D63658754
	for <doc-jp@jp.freebsd.org>; Wed, 6 Feb 2002 22:06:04 +0900 (JST)
	(envelope-from WSCH1739@eudoramail.com)
Received: from proliant800.panaviajes.com ([209.88.62.220])
 by epicac.cable.net.co (iPlanet Messaging Server 5.1 (built May  7 2001))
 with SMTP id <0GR400B4W4DIAU@epicac.cable.net.co> for doc-jp@jp.freebsd.org;
 Wed, 06 Feb 2002 08:05:46 -0500 (COT)
Received: from mx2.eudoramail.com ([204.32.146.158])
 by proliant800.panaviajes.com with Microsoft SMTPSVC(5.0.2195.2966); Wed,
 06 Feb 2002 08:00:13 -0500
Date: Wed, 06 Feb 2002 07:05:42 +0000
From: WSCH1739@eudoramail.com
To: <Money.In.Motion>
Message-id: <0000394e6b2c$00002432$00001890@mx2.eudoramail.com>
MIME-version: 1.0
Content-type: text/html; charset=iso-8859-1
Content-transfer-encoding: quoted-printable
X-OriginalArrivalTime: 06 Feb 2002 13:00:15.0218 (UTC)
 FILETIME=[384EDD20:01C1AF0E]
Reply-to: WSCH1739@eudoramail.com
Precedence: list
X-Distribute: distribute version 2.1 (Alpha) patchlevel 24e+011218
X-Sequence: doc-jp 8688
Subject: [doc-jp 8688] WSCH : A Revolutionary Acne Treatment and More  RL
Errors-To: owner-doc-jp@jp.FreeBSD.org
Sender: owner-doc-jp@jp.FreeBSD.org
X-Originator: WSCH1739@eudoramail.com

<html><head><meta http-equiv=3DContent-Type content=3D"text/html; charset=3D=
windows-1252"><title>SPECIAL ALERT</title></head><body><table cellSpacing=3D=
0 cellPadding=3D0 width=3D604 bgColor=3D#000000 border=3D0><tr><td width=3D=
604><div align=3Dleft>
  <img border=3D0 src=3Dhttp://www.betaqa.com/ecard/pix/upload/886598225.j=
pg width=3D600 height=3D99></div></td></tr></table><table cellSpacing=3D0 =
cellPadding=3D2 width=3D602 border=3D0 height=3D2863><tr><td vAlign=3Dtop =
align=3Dleft bgColor=3D#000000 height=3D2859><table cellSpacing=3D0 cellPa=
dding=3D3 width=3D561 bgColor=3D#ffffff border=3D0 height=3D2875><tr><td b=
gColor=3D#000000 height=3D19><table cellSpacing=3D0 cellPadding=3D0 width=3D=
591 border=3D0><tr><td vAlign=3Dcenter align=3Dleft width=3D591><p align=3D=
center><b><font face=3D"Times New Roman, Times, serif" color=3D#FFFFDD>Spe=
cial Alert </font><font face=3D"Times New Roman, Times, serif" size=3D2 co=
lor=3D#FFFFDD>:</font><font face=3D"Times New Roman, Times, serif" size=3D=
2 color=3D#FFFFE1> </font><font face=3D"Times New Roman, Times, serif" col=
or=3D#FFFFFF>&nbsp;WASATCH&nbsp; PHARMACEUTICALS </font><font face=3D"Time=
s New Roman, Times, serif" size=3D2 color=3D#FFFFFF>&nbsp;</font><font fac=
e=3D"Times New Roman, Times, serif" color=3D#FFFFDD>(OTCBB: WSCH)</font></=
b></td></tr></table></td></tr><tr><td bgColor=3D#ffffff height=3D6><img he=
ight=3D4 src=3Dhttp://www.businessworldwide.net/sik/spacer.gif width=3D592=
 NOSEND=3D1></td></tr><tr><td vAlign=3Dtop align=3Dleft height=3D816><div =
align=3Dright><table cellSpacing=3D0 cellPadding=3D3 width=3D565 border=3D=
0 style=3D"border-collapse: collapse" bordercolor=3D#111111 height=3D1 ali=
gn=3Dright><tr><td vAlign=3Dtop align=3Dleft width=3D5 rowspan=3D6 height=3D=
638><table cellSpacing=3D0 cellPadding=3D3 width=3D288 border=3D0 height=3D=
872><tr bgColor=3D#099DF7><td height=3D1 width=3D25><p align=3Dleft><img b=
order=3D0 src=3Dhttp://www.mbworld.org/upload/2001/arrow25.gif width=3D25 =
height=3D25><font face=3DBatang style=3D"font-size: 11pt"></font></td><td =
height=3D1 width=3D251><p align=3Dleft><span style=3D"font-weight: 700"><f=
ont face=3D"Times New Roman" style=3D"font-size: 13pt">TOP&nbsp;4 REASONS =
TO BUY WSCH</font></span></td></tr><tr><td colSpan=3D2 height=3D4 width=3D=
282><img height=3D2 src=3Dhttp://www.businessworldwide.net/sik/spacer.gif =
width=3D280 NOSEND=3D1></td></tr><tr><td vAlign=3Dtop align=3Dright width=3D=
25 height=3D64><font face=3D"Verdana, Geneva, Helvetica, Arial, sans-serif=
" size=3D2><b>1.</b></font></td><td vAlign=3Dtop align=3Dleft width=3D251 =
height=3D64><font face=3D"Times New Roman">The products and medical therap=
ies developed by WSCH represent possibly the <b>most important breakthroug=
h</b> in the field of Dermatology in the last fifty years.</font></td></tr=
><tr><td vAlign=3Dtop align=3Dright width=3D25 height=3D48><b><font face=3D=
"Verdana, Geneva, Helvetica, Arial, sans-serif" size=3D2>2.</font></b></td=
><td vAlign=3Dtop align=3Dleft width=3D251 height=3D48><font face=3D"Times=
 New Roman">WSCH anticipates <b>FDA approval</b> on seven over-the-counter=
 products within the next year, which will provide significant revenue in =
the retail drug market.</font></td></tr><tr><td vAlign=3Dtop align=3Dright=
 width=3D25 height=3D80><b><font face=3D"Verdana, Geneva, Helvetica, Arial=
, sans-serif" size=3D2>3.</font></b></td><td vAlign=3Dtop align=3Dleft wid=
th=3D251 height=3D80><font face=3D"Times New Roman">WSCH has experienced a=
 <b>success rate of 90%</b> during clinical studies, completely eliminatin=
g skin disease from 90% of all patients treated.</font></td></tr><tr><td v=
Align=3Dtop align=3Dright width=3D25 height=3D80><b><font face=3D"Verdana,=
 Geneva, Helvetica, Arial, sans-serif" size=3D2>4.</font></b></td><td vAli=
gn=3Dtop align=3Dleft width=3D251 height=3D80><font face=3D"Times New Roma=
n">By year five, WSCH plans to have annualized revenue over <b>$525 millio=
n</b> and over <b>$125 million in EBIT</b>.&nbsp; This does not take into =
account income from OTC products which will be substantial.</font><p>&nbsp=
;</td></tr><tr bgColor=3D#099DF7><td height=3D1 width=3D25><p align=3Dleft=
><img border=3D0 src=3Dhttp://www.mbworld.org/upload/2001/arrow25.gif widt=
h=3D25 height=3D25><font face=3DBatang style=3D"font-size: 11pt"></font></=
td><td height=3D1 width=3D251><p align=3Dleft><span style=3D"font-weight: =
700"><font face=3D"Times New Roman" style=3D"font-size: 13pt">&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PROJECT=
IONS, OBJECTIVES AND STATISTICS</font></span></td></tr><tr><td vAlign=3Dto=
p align=3Dleft width=3D276 height=3D548 colspan=3D2><p class=3DMsoNormal>&=
nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp; Over a five year period, AISC (WSCH's subsidiary) plans to establi=
sh <b>350 clinics in over 100 major population areas</b>.&nbsp;The company=
 plans to hire over 150 medical doctors for these clinics, train over 1,00=
0 medical assistants and treat over <b>2,000,000 patients</b>. Also by yea=
r five, WSCH plans to have annualized over <u>$525 million in revenue and =
over $125 million in EBIT</u>. This does not take into account income from=
 OTC products which will be substantial.</p><p class=3DMsoNormal><span sty=
le=3D"font-size: 12.0pt; font-family: Times New Roman">As of 1991, there w=
ere approximately <b>14 million </b>chronic acne and eczema patients annua=
lly in the United States,&nbsp;with the highest percentage between 18 to 4=
4 years of&nbsp;age. The actual number of patients with any type of acne&n=
bsp;Is significantly higher.&nbsp;<b>Seven billion dollars is spent&nbsp;a=
nnually </b>on dermatological pharmaceutical products for&nbsp;these disor=
ders.</span></p><p class=3DMsoNormal><span style=3D"font-size: 12.0pt; fon=
t-family: Times New Roman">In 1994, the teen population reached 25 million=
 During&nbsp;the next decade, it will grow at <b>nearly twice the rate of=
&nbsp;the overall population</b> (according to U.S. Census Bureau&nbsp;pro=
jections).&nbsp;Acne patients are primarily teenagers,&nbsp;whereas eczema=
 patients range from infants to the&nbsp;elderly</span>.</td></tr></table>=
</td><td vAlign=3Dtop align=3Dleft width=3D277 rowspan=3D6 height=3D1></td=
><td vAlign=3Dtop align=3Dleft width=3D239 height=3D1><table cellSpacing=3D=
0 cellPadding=3D4 border=3D0 width=3D250><tr><td vAlign=3Dcenter align=3Dm=
iddle bgColor=3D#099DF7 height=3D118 width=3D282><table cellSpacing=3D0 ce=
llPadding=3D0 width=3D260 bgColor=3D#ffffff border=3D0><tr><td vAlign=3Dto=
p align=3Dleft height=3D101><table cellSpacing=3D0 cellPadding=3D4 width=3D=
235 border=3D0 align=3Dleft><tr><td width=3D123><b><font face=3DArial colo=
r=3D#339933 style=3D"font-size: 9pt">&nbsp;&nbsp;&nbsp; </font><font face=3D=
Arial color=3D#339933 size=3D2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SYMBOL:</fon=
t></b></td><td width=3D96><b><font face=3DArial size=3D2>&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp; WSCH</font></b></td></tr><tr><td width=3D123><b>=
<font face=3DArial style=3D"font-size: 9pt" color=3D#339933>&nbsp;&nbsp;&n=
bsp;&nbsp;&nbsp;&nbsp; CURRENT PRICE:</font></b></td><td width=3D96><font =
face=3D"Bookman Old Style" size=3D2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <=
/font><font face=3D"Times New Roman"><b>$0.0</b></font><b><font face=3D"Ti=
mes New Roman">59</font></b></td></tr><tr><td width=3D123><font face=3DAri=
al color=3D#339933><b><font style=3D"font-size: 9pt">&nbsp;&nbsp;&nbsp;&nb=
sp;&nbsp;&nbsp; 52 WEEK HIGH:</font></b></font></td><td width=3D96><font f=
ace=3D"Bookman Old Style" size=3D2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </=
font><b><font face=3D"Times New Roman">$27.50</font></b></td></tr><tr><td =
width=3D123><b><font face=3DArial style=3D"font-size: 9pt" color=3D#339933=
>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 52 WEEK LOW:</font></b></td><td widt=
h=3D96><font face=3D"Bookman Old Style" size=3D2>&nbsp;&nbsp;&nbsp;&nbsp; =
</font><font face=3D"Times New Roman"><b>&nbsp; <font color=3D#339933>$0.0=
</font></b></font><b><font face=3D"Times New Roman" color=3D#339933>56</fo=
nt></b></td></tr></table></td></tr></table></td></tr><tr><td vAlign=3Dcent=
er align=3Dleft width=3D282><img height=3D2 src=3Dhttp://www.businessworld=
wide.net/sik/spacer.gif width=3D280 NOSEND=3D1></td></tr></table><table ce=
llSpacing=3D0 cellPadding=3D3 width=3D288 border=3D0 height=3D1><tr bgColo=
r=3D099df7><td height=3D1 width=3D1><p align=3Dleft><img border=3D0 src=3D=
http://www.mbworld.org/upload/2001/arrow25.gif width=3D25 height=3D25><fon=
t face=3DBatang style=3D"font-size: 11pt"></font></td><td height=3D1 width=
=3D500><p align=3Dleft><span style=3D"font-weight: 700"><font face=3D"Time=
s New Roman" style=3D"font-size: 13pt">COMPANY BACKGROUND</font></span></t=
d></tr></table></td></tr><tr><td vAlign=3Dtop align=3Dleft width=3D284 hei=
ght=3D1><p class=3DMsoNormal>Wasatch Pharmaceutical, Inc. is a fourteen ye=
ar old company with a record of outstanding achievements in the field of D=
ermatology. Dermatology.&nbsp;Under the name of its subsidiary, American I=
nstitute of Skin Care <b>(AISC)</b>, Wasatch has operated two prototype cl=
inics for the last five years where the products and medical therapies hav=
e been tested and proven on hundreds of patients. The Company's activities=
 have been centered on research in the area of <b>serious skin diseases</b=
>.&nbsp;<font face=3D"Times New Roman">A concurrent discovery and benefit =
is WSCH's dramatic success in the area of skin rejuvenation.</font></td></=
tr><tr><td vAlign=3Dtop align=3Dleft width=3D284 height=3D11><font face=3D=
"Times New Roman">Seeing the high growth potential from major funding, WSC=
H elected to <b>become a public company</b> less than two years ago.</font=
><p><font face=3D"Times New Roman">Wasatch's major successes in the area o=
f skin diseases include:</font></td></tr><tr><td vAlign=3Dtop align=3Dleft=
 width=3D284 height=3D14><font face=3D"Times New Roman"><b>Cystic Acne, Ec=
zema, Seborrhea, Contact Dermatitis, Molluscum, Folliculitis, Acne Rosacea=
 and less prevalent skin diseases.</b></font></td></tr><tr><td vAlign=3Dto=
p align=3Dleft width=3D284 height=3D19><font face=3D"Times New Roman">Inte=
restingly, these skin disorders account for more than <b>70% of all busine=
ss</b> in the field of dermatology for which there are very few (if any) s=
afe, effective therapies like those developed by <b>Wasatch.</b></font></t=
d></tr><tr><td vAlign=3Dtop align=3Dleft width=3D284 height=3D29><font fac=
e=3D"Times New Roman">Because the therapies developed by Wasatch <b>domina=
te</b> this area of medicine, WSCH has elected to market its products via =
company-owned clinics throughout the United States.&nbsp;This decision has=
 resulted in the establishment of <b>two research clinics</b> in Utah for =
the purpose of implementing procedures within the clinics pursuant to test=
ing and confirming the results that were achieved in past clinical trials.=
 </font>Due to its <b>success rate of 90% on hundreds of patients over a f=
ive year period</b>, WSCH's clinics are now on line with insurance provide=
rs independent of HMOs. Efforts to establish Preferred Providership status=
 with HMOs are presently being pursued.</td></tr></table></div></td></tr><=
tr><td height=3D23><table cellSpacing=3D0 cellPadding=3D2 width=3D592 bgCo=
lor=3D#006633 border=3D0><tr><td align=3Dmiddle width=3D545 bgColor=3D#099=
df7><b><font face=3D"Times New Roman, Times, serif">THIS JUST IN : WSCH BR=
EAKING NEWS</font></b></td></tr></table></td></tr><tr><td vAlign=3Dtop ali=
gn=3Dleft height=3D1981>&nbsp;<table cellSpacing=3D0 cellPadding=3D4 width=
=3D587 border=3D0 height=3D1845><tr><td vAlign=3Dtop align=3Dleft height=3D=
737><h2><span style=3D"font-size: 13pt">Wasatch Pharmaceutical Inc. Announ=
ces a New Physician Marketing Campaign and Listing On German Stock Exchang=
es</span></h2> <h2><span style=3D"font-weight: 400"><font face=3D"Times Ne=
w Roman" size=3D3>MURRAY, Utah--(BUSINESS WIRE)--Nov. 27, 2001--Wasatch Ph=
armaceutical Inc. (OTCBB:<a href=3Dhttp://finance.yahoo.com/q?s=3Dwsch.ob&=
d=3Dt>WSCH</a> - <a href=3Dhttp://biz.yahoo.com/n/w/wsch.ob.html>news</a>)=
 CEO Gary Heesch announced today a marketing campaign directed to physicia=
ns. A direct link has been established on a physician recruiting Web site =
making available therapies for the treatment of cystic acne, acne, follicu=
litis and skin rejuvenation. Physicians will find the benefits of these tr=
eatment therapies by logging on to the <b>&quot;X Acne&quot; link at the P=
hysician Search website</b>. This physician search Web site typically rece=
ives over <b>200,000 hits per month</b>. Mr. Heesch reminded, &quot;Our tr=
eatment therapy products are also available via the AISC Online Store.&quo=
t;</font></span></h2><p><font face=3D"Times New Roman">These skin treatmen=
t products come in kit form providing a 90-day supply to patients for the =
full treatment program. Included in the kit is an instructional video on t=
he treatment therapy allowing the patient to use these products in their h=
ome. The therapies, when used as instructed, achieve a <b>success rate of =
eradication in excess of 90% with no side effects of any consequence</b>. =
Previously, these therapies and associated products were only available th=
rough the two prototype clinics in Utah. The availability of these product=
s will open the way for family practitioners, pediatricians, internists an=
d other primary care physicians to retain their patients under their care =
during the treatment of these common skin disorders. <b>The benefit to ins=
urance providers is the potential to save millions of dollars in reimburse=
ment costs by freeing the physician and the patient from ongoing treatment=
</b></font></p><p><font face=3D"Times New Roman">In the coming year, <u>s=
ix additional therapies will be made available</u> for a broad range of sk=
in disorders that are badly in need of successful therapies.</font></p><p>=
<font face=3D"Times New Roman">Gary Heesch also announced the listing of W=
asatch Pharmaceutical stock on the <b>Frankfurt and Berlin Exchanges in Ge=
rmany</b>. Active trading on these exchanges will take place upon the comp=
letion of a research report in Germany. Said Mr. Heesch, &quot;We feel thi=
s is a significant event as Wasatch will gain <b>wider exposure</b> as a l=
eader in dermatology and will put <u>buying</u> <u>pressure on its stock t=
o <b>reflect the true value</b> </u>of a company that has committed years =
of research and development of products that allow people with serious ski=
n disorders to live normal and more productive lives.&quot;</font></p><p><=
font face=3DArial size=3D1><i>There may be forward-looking statements in t=
his release. Investors are cautioned that such forward-looking statements =
involve risks and uncertainties, including, without limitation, continued =
acceptance of the Company's products, increased levels of competition, new=
 products introduced by competitors, changes in the rates of subscriber ac=
quisition and retention, and other risks detailed from time to time in the=
 Company's periodic reports filed with the Securities and Exchange Commiss=
ion.</i></font><font face=3D"Times New Roman"></font></td></tr><tr><td vAl=
ign=3Dtop align=3Dleft height=3D10 bgcolor=3D#099DF7><p align=3Dcenter><b>=
A LOOK AT THE COMPETITION</b></td></tr><tr><td vAlign=3Dtop align=3Dleft h=
eight=3D64><span style=3D"font-size: 12.0pt; font-family: Times New Roman"=
>Dermatologists are the primary competitors of WSCH's clinics. Dermatologi=
sts specialize in the treatment of skin disorders and prescribe medication=
s to treat the disorder. However, competing products address the <b>sympto=
ms</b> of acne and eczema, <b>not the cause.&nbsp;</b></span><p><span styl=
e=3D"font-size: 12.0pt; font-family: Times New Roman">The competition's sk=
in care treatments include prescription medications (oral and external use=
 drugs prescribed by dermatologists and other doctors) and over-the-counte=
r products.</span></p><p class=3DMsoNormal><b>Several common prescription =
medications include:&nbsp;</b></p><p class=3DMsoNormal>1) E-Mycin for oral=
 and topical use, 2) Cleocin for oral and topical use, 3) Tetracycline for=
 oral and topical use, and 4) Accutane for oral use only.</p><p class=3DMs=
oNormal><b>Over-the-counter acne medications include:&nbsp;</b><br> 1) Cle=
arasil and Oxy creams, 2) generic brand creams, 3) medicated pads, and 4) =
medicated soaps.</p><p class=3DMsoNormal><i><u>Many of the competition's o=
ral medications have serious side effects.</u></i></p><p class=3DMsoNormal=
><span style=3D"font-size: 12.0pt; font-family: Times New Roman">Costs for=
 competing treatments range from $2.50 for medicated soaps to $200 for Acc=
utane oral medication prescription. Treatments are on-going.&nbsp;Over tim=
e a person can spend an <b>unlimited amount of money</b> on such treatment=
s.&nbsp;An example would be someone who spent $1,500 for a 22 week program=
 of Accutane which includes blood testing.&nbsp;Another example would be s=
omeone who has had acne for many years and has spent in excess of $34,000.=
</span></p><p class=3DMsoNormal>At this time there is <b>no known competit=
or </b>who treats the causes of these skin disorders and no competitor can=
 claim a <b>success rate</b> equal to that of Wasatch's treatments.</td></=
tr><tr><td vAlign=3Dtop align=3Dleft width=3D587 height=3D19 bgcolor=3D#09=
9DF7><p align=3Dcenter><b>A FINAL WORD ABOUT WSCH</b></td></tr><tr><td vAl=
ign=3Dtop align=3Dleft height=3D112><p class=3DMsoNormal>With a proven suc=
cess rate of 90% in a field that affects so many of our lives, Wasatch has=
 clearly positioned itself in a market <b>hungry and desperate</b> for suc=
cessful products and treatment.&nbsp;WSCH has recently expanded its market=
ing presence (as seen in the above press release) and will continue to agg=
ressively broaden awareness over the near term. The listing of <b>WSCH</b>=
 on the German stock exchange is another sign of the company's credibility=
 and ambitious plans to establish itself as a <b>major global player</b> i=
n the field of dermatology.</p><b><span style=3D"FONT-SIZE: 10pt"><font fa=
ce=3DVerdana color=3D#000000>&nbsp;</font></span></b>WSCH has taken on a c=
ompletely different approach.&nbsp;By addressing the causes of skin disord=
ers rather than the symptoms, WSCH will help to successfully eliminate ski=
n disease altogether. Given the following:<p class=3DMsoNormal>1. Successf=
ul 14-year history and plans for expansion<br> 2. Impressive revenue proje=
ctions ($525 million+ annualized&nbsp;by year 5 and $125 million in EBIT)<=
br> 3. Virtually unmatched success rate of 90%...</p><p class=3DMsoNormal>=
<span style=3D"font-size: 12.0pt; font-family: Times New Roman">...<b>and =
so much more, WSCH will certainly be watched by savvy investors for some t=
ime to come.</b></span></td></tr><tr><td vAlign=3Dtop align=3Dleft width=3D=
587 height=3D19><p align=3Dcenter><b><font face=3DVerdana color=3D#099DF7 =
size=3D2>To be removed from future mailings, please reply to this email wi=
th &quot;Remove&quot; in the subject line</font></b></td></tr><tr><td vAli=
gn=3Dtop align=3Dleft height=3D371><b><font face=3DVerdana color=3D#efefef=
 size=3D1><br> </font></b><font face=3D"Times New Roman" style=3D"font-siz=
e: 9pt">DISCLAIMER:&nbsp;<br> Information within this email contains &quot=
;forward looking statements&quot; within the meaning of Section 27A of the=
 Securities Act of 1933 and Section 21B of the Securities Exchange Act of =
1934. Any statements that express or involve discussions with respect to p=
redictions, expectations, beliefs, plans, projections, objectives, goals, =
assumptions or future events or performance are not statements of historic=
al fact and may be &quot;forward looking statements.&quot;<br> <br> Forwar=
d looking statements are based on expectations, estimates and projections =
at the time the statements are made that involve a number of&nbsp;risks an=
d uncertainties which could cause actual results or events to differ mater=
ially from those presently anticipated. Forward looking statements in this=
 action may be identified through the use of words such as &quot;projects&=
quot;, &quot;foresee&quot;, &quot;expects&quot;, &quot;will,&quot;&nbsp; &=
quot;anticipates,&quot; &quot;estimates,&quot; &quot;believes,&quot; &quot=
;understands&quot; or that by statements indicating certain actions &quot;=
may,&quot; &quot;could,&quot; or &quot;might&quot; occur.&nbsp; All inform=
ation provided within this email pertaining to investing, stocks, securiti=
es must be understood as information provided and not investment advice. E=
merging Growth Stock Alert advises all readers and subscribers to seek&nbs=
p;advice from a registered professional securities representative before d=
eciding to trade in stocks featured within this email.&nbsp; None of the m=
aterial within this report shall be construed as any kind of investment ad=
vice.<br> <br> In compliance with the Securities Act of 1933, Section17(b)=
, Emerging Growth Stock Alert discloses the receipt of $50,000 cash from a=
 third party for the publication of this report and additional&nbsp;servic=
es related to WSCH. Be aware of an inherent conflict of interest resulting=
 from such compensation.&nbsp; In addition, Emerging Growth Stock Alert in=
tends to receive three million five hundred thousand unrestricted shares o=
f WSCH from a third party for the publication of this report and additiona=
l services related to WSCH.&nbsp; Be aware of an inherent conflict of inte=
rest due to our intent to profit from the liquidation of these shares. Par=
t or all of this position may be sold at any time, even after we have made=
 positive statements regarding the above company.&nbsp; All&nbsp;factual i=
nformation in this report was gathered from public sources, including but =
not limited to SEC filings, Company Press Releases, and the company's webs=
ite at wasatchpharm.com.&nbsp;Emerging Growth Stock Alert believes this in=
formation to be reliable but can make no guarantee as to its accuracy or c=
ompleteness. Use of the material within this email constitutes your accept=
ance of these terms.</font><font face=3DVerdana size=3D1><br> &nbsp;</font=
></td></tr><tr><td vAlign=3Dtop align=3Dleft height=3D36><p align=3Dcenter=
><b><font face=3DVerdana color=3D#099DF7 size=3D2>To be removed from futur=
e mailings, please reply to this email with &quot;Remove&quot; in the subj=
ect line</font></b></td></tr></table></td></tr></table></td></tr></table><=
/body></html>



